Trial Profile
An Open-Label, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Elderly (≥ 75 Years of Age) and Healthy Younger Adult Subjects (18 to 55 Years of Age, Inclusive)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Esketamine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 25 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Jan 2015 New trial record